China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition
The National Joint Procurement Office (NJPO) has issued the Notice on Corporate Affiliations for the...
Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis
Hisun Pharmaceutical (SHA: 600267) announced it has entered into an exclusive licensing agreement with EnliTISA...
Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms
The Fujian Provincial Medical Security Bureau has implemented the “Ten Measures to Support the Innovative...
China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
China’s National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use...
CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted...
Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals,...
Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has...
Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application...
China’s Health Authorities Issue Comprehensive Medical Equipment Centralized Procurement Framework with Tiered Implementation and High-Value Equipment Database
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine (NATCM), and National Disease...
Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules – Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam...
Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Commission has approved Boey...
GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III...
Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution)...
Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca
Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed...
CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III...
CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of...
Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
Immvira Bioscience Inc., a clinical-stage biotechnology company founded in 2015, has filed its prospectus for...
Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
Abbott Laboratories (NYSE: ABT) reported second-quarter 2026 financial results with total revenue of $12.593 billion,...
Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has...
Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...